Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity US$ 28.71 Min. order: 1 piece ★★★★★ 4.1 (149 reviews) Sold : Login>>
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved US$ 29.59 Min. order: 1 piece ★★★★★ 4.7 (245 reviews) Sold : Login>>
The pharma race to develop increasingly more potent incretin-based therapeutics—what is for the clinicians to know US$ 27.58 Min. order: 1 piece ★★★★★ 4.8 (203 reviews) Sold : Login>>
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants - Gabe - 2024 - Diabetes, Obesity and Metabolism US$ 25.09 Min. order: 1 piece ★★★★★ 4.2 (168 reviews) Sold : Login>>
CagriSema Demonstrates Significant Weight Loss at 68 Weeks US$ 25.57 Min. order: 1 piece ★★★★★ 4.2 (230 reviews) Sold : Login>>
What Is Cagrilintide? The Amylin Analog Peptide in Combination Metabolic Research US$ 28.98 Min. order: 1 piece ★★★★★ 4.8 (218 reviews) Sold : Login>>